Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal

被引:0
|
作者
Herrera, Bobby Brooke [1 ,2 ,3 ,4 ,5 ]
Chaplin, Beth [5 ]
Mboup, Souleymane [6 ]
Abdullahi, Adam [7 ,8 ]
He, Michelle [5 ]
Fisher, Sydney M. [5 ]
Akanmu, Sulaimon [9 ]
Chang, Charlotte A. [5 ]
Hamel, Donald J. [5 ]
Gupta, Ravindra K. [7 ,8 ]
Kanki, Phyllis J. [5 ]
机构
[1] Rutgers State Univ, Rutgers Global Hlth Inst, New Brunswick, NJ USA
[2] Rutgers State Univ, Dept Med, Div Allergy Immunol & Infect Dis, New Brunswick, NJ USA
[3] Rutgers State Univ, Child Hlth Inst New Jersey, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[4] Mir Biosci Inc, Dunellen, NJ USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[6] Inst Rech Sante Surveillance Epidemiol & Format IR, Dakar, Senegal
[7] Cambridge Inst Therapeut Immunol & Infect Dis CITI, Cambridge, England
[8] Univ Cambridge, Dept Med, Cambridge, England
[9] Univ Lagos, Lagos Univ Teaching Hosp, Coll Med, Lagos, Nigeria
关键词
SARS-CoV-2; antibody; cellular responses; cross-reactivity; Senegal; VIRUS-INFECTION; RESILIENCE; TARGETS; HIV-2;
D O I
10.3389/fpubh.2025.1522733
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background The COVID-19 pandemic had a severe impact globally, yet African populations exhibited unexpectedly lower rates of severe disease and mortality. We investigated the potential role of pre-existing immunity in shaping the epidemiology of COVID-19 in Africa.Methods Plasma collected from Senegalese female sex workers prior to the COVID-19 pandemic was screened for SARS-CoV-2 and human coronavirus (hCoV) antibodies by virion immunoblots. For antibody-reactive plasma, paired peripheral blood mononuclear cells were stimulated by fusion proteins and IFN-gamma cellular responses were assessed via ELISPOT.Results We observed substantial levels of pre-existing cross-reactive immunity to SARS-CoV-2, stemming from prior exposure to seasonal hCoVs. Our antibody analysis revealed a 23.5% (47/200) seroprevalence rate against SARS-CoV-2 nucleocapsid (N). These samples were then probed for antibodies against hCoV spike (S) and/or N antigens; 85.1% (40/47), 70.2% (33/47), and 95.7% (45/47) were antibody reactive against hCoV-229E, hCoV-OC43, or hCoV-HKU1, respectively. Our analysis of cellular responses also demonstrated cross-reactivity to SARS-CoV-2 with 80.0% (36/45) and 82.2% (37/45) showing IFN-gamma responses against S and N, respectively. A unique pre-pandemic subject had cross-reactive SARS-CoV-2 S antibodies with detectable neutralization and cross-reactive cellular responses.Conclusion These findings suggest that prior hCoV exposure may induce cross-reactive adaptive immunity, potentially contributing to protection against COVID-19. Our study provides unique data on the dynamics of hCoV and SARS-CoV-2 immunity in Senegal and underscores the importance of understanding the role of pre-existing immunity in shaping COVID-19 outcomes globally.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
    Ahn, Terrie S.
    Han, Brandon
    Krogstad, Paul
    Bun, Chantana
    Kohn, Lisa A.
    Garcia-Lloret, Maria I.
    Damoiseaux, Robert
    Butte, Manish J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 876 - 877
  • [22] SARS-CoV-2-cross-reactive T cells identified in pre-pandemic lower airway samples
    Maini, Mala K.
    Diniz, Mariana O.
    NATURE IMMUNOLOGY, 2022, 23 (09) : 1307 - 1308
  • [24] Immune responses of lung transplant recipients against SARS-CoV-2 and common respiratory coronaviruses: Evidence for pre-existing cross-reactive immunity
    Bansal, Sandhya
    Fleming, Timothy
    Canez, Jesse
    Maine, Gabriel N.
    Bharat, Ankit
    Walia, Rajat
    Tokman, Sofya
    Smith, Michael A.
    Tiffany, Brian
    Bremner, Ross M.
    Mohanakumar, T.
    TRANSPLANT IMMUNOLOGY, 2023, 81
  • [25] Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
    Moyo-Gwete, Thandeka
    Madzivhandila, Mashudu
    Makhado, Zanele
    Ayres, Frances
    Mhlanga, Donald
    Oosthuysen, Brent
    Lambson, Bronwen E.
    Kgagudi, Prudence
    Tegally, Houriiyah
    Iranzadeh, Arash
    Doolabh, Deelan
    Tyers, Lynn
    Chinhoyi, Lionel R.
    Mennen, Mathilda
    Skelem, Sango
    Marais, Gert
    Wibmer, Constantinos K.
    Bhiman, Jinal N.
    Ueckermann, Veronica
    Rossouw, Theresa
    Boswell, Michael
    de Oliveira, Tulio
    Williamson, Carolyn
    Burgers, Wendy A.
    Ntusi, Ntobeko
    Morris, Lynn
    Moore, Penny L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22): : 2161 - 2163
  • [26] Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
    Bullen, Georgia
    Galson, Jacob D.
    Hall, Gareth
    Villar, Pedro
    Moreels, Lien
    Ledsgaard, Line
    Mattiuzzo, Giada
    Bentley, Emma M.
    Masters, Edward W.
    Tang, David
    Millett, Sophie
    Tongue, Danielle
    Brown, Richard
    Diamantopoulos, Ioannis
    Parthiban, Kothai
    Tebbutt, Claire
    Leah, Rachael
    Chaitanya, Krishna
    Ergueta-Carballo, Sandra
    Pazeraitis, Deividas
    Surade, Sachin B.
    Ashiru, Omodele
    Crippa, Lucia
    Cowan, Richard
    Bowler, Matthew W.
    Campbell, Jamie I.
    Lee, Wing-Yiu Jason
    Carr, Mark D.
    Matthews, David
    Pfeffer, Paul
    Hufton, Simon E.
    Sawmynaden, Kovilen
    Osbourn, Jane
    McCafferty, John
    Karatt-Vellatt, Aneesh
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
    Tai, Wanbo
    Zhang, Xiujuan
    He, Yuxian
    Jiang, Shibo
    Du, Lanying
    ANTIVIRAL RESEARCH, 2020, 179
  • [28] Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
    Kawashiro, Keita
    Suzuki, Rigel
    Nogimori, Takuto
    Tsujino, Shuhei
    Iwahara, Naoya
    Hirose, Takayuki
    Okada, Kazufumi
    Yamamoto, Takuya
    Fukuhara, Takasuke
    Hotta, Kiyohiko
    Shinohara, Nobuo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] Quantitative SARS-CoV-2 Antibody Screening of Healthcare Workers in the Southern Part of Kyoto City During the COVID-19 Pre-pandemic Period
    Fujita, Kohei
    Kada, Shinpei
    Kanai, Osamu
    Hata, Hiroaki
    Odagaki, Takao
    Satoh-Asahara, Noriko
    Tagami, Tetsuya
    Yasoda, Akihiro
    FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [30] Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic
    Pedersen, Jannie
    Koumakpayi, Ismael Herve
    Babuadze, Giorgi
    Baz, Mariana
    Ndiaye, Oumar
    Faye, Oumar
    Diagne, Cheikh Tidiane
    Dia, Ndongo
    Naghibosadat, Maedeh
    McGeer, Allison
    Muberaka, Samira
    Moukandja, Irene P.
    Ndidi, Stella
    Tauil, Carlos B.
    Lekana-Douki, Jean-Bernard
    Loucoubar, Cheikh
    Faye, Ousmane
    Sall, Amadou
    Magalhaes, Kelly G.
    Weis, Nina
    Kozak, Robert
    Kobinger, Gary P.
    Fausther-Bovendo, Hugues
    SCIENTIFIC REPORTS, 2022, 12 (01)